Short description
An Oncology Company Pioneering a Novel Therapy for Solid Tumors
Description
Novocure™ is dedicated to the development of tumor treating fields therapy (NovoTTF™ Therapy), a new weapon for patients and physicians in the battle against cancer. NovoTTF Therapy is a novel anti-mitotic treatment that has been shown to slow or reverse tumor progression by inducing cell death in certain solid tumors. The company pioneered the concept that the electric properties of cells can be used as an effective target for an anti-neoplastic therapy.
Last funding
Blurry Noaccess
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Jersey, Arkansas, United States, North America
Founded on
January 1, 2000
Exited on
October 9, 2015
Went public on
October 9, 2015
Stock symbol
NVCR
Non-profit?
No
Acquired?
No
Employees count
1001-5000
Revenue range
$34056 - 789030
Sign in for full access
Investors
Blurry Noaccess, Noaccessforu, No Way, Noaccessforu, Noaccessforu, Absolutely Noaccess, Noaccess, Cannot Access
Sign in for full access
Founders
William F. Doyle, Yoram Palti